Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBarr (A.G.) Regulatory News (BAG)

Share Price Information for Barr (A.G.) (BAG)

Share Price is delayed by 15 minutes
Get Live Data
618.00    5.00 (0.82%)
Bid:
617.00
Ask:
619.00
Spread: 2.00 (0.324%)
Market Cap: £685.83m
BAG Live PriceLast checked at - London Stock Exchange

Intraday Barr (A.G.) Share Chart

Trading Update

28 Jan 2025 07:00

RNS Number : 8582U
Barr(A.G.) PLC
28 January 2025
 

IMMEDIATE RELEASE 28 January 2025

A.G. BARR p.l.c

Trading Update

 

 Sustained revenue growth and double digit profit growth

A.G. BARR p.l.c., the multi-beverage business with a portfolio of market-leading UK brands including IRN-BRU, Rubicon, Boost and FUNKIN, today announces a trading update for the full year ended 25 January 2025 (2024/25).

Revenue in 2024/25 is expected to be c.£420m (2023/24: £400m), representing c.5% year-on-year growth.

Full year adjusted operating margin is expected to show strong improvement to c.13.5% (2023/24:12.3%), helping to drive double digit profit1 growth.

Highlights

Soft Drinks:  All three core soft drinks brands - IRN-BRU, Rubicon and Boost - performed strongly. Rubicon was the stand-out performer, achieving another year of double digit revenue growth. IRN-BRU also delivered strong revenue growth and is now one of the top five carbonates in the UK. The Boost strategy, to focus on value over volume and synergy benefits, gained momentum in H2 with a step up in profitability. The brand is now fully integrated into our commercial operation and the insourcing of manufacturing remains on track.

FUNKIN: FUNKIN's ready-to-drink business continued to grow at pace through retail distribution gains and innovation. This went some way to mitigate on-going challenges within the on-premise market.

Strategic Programme: We have successfully completed the projects to strengthen our convenience channel route to market and integrate Boost into our Soft Drinks business. These projects deliver significant commercial and operational synergies. As previously advised, they give rise to a one-off cost of c.£5m in the 2024/25 financial year, which will be treated as an adjusting item.

Capital Investment:  The multi-year supply chain investment programme continues on plan, supporting brand growth, efficiency improvements and synergy benefits.  Overall capital spend in the year of c.£19m included a new small format PET line and an upgraded large format PET line at our Cumbernauld site, providing increased capacity and capability.

Balance Sheet & Cash Flow: We remain a highly cash generative business, ending the year with more than £60m of net cash (2023/24: £53.6m).

People: Our talent development continues with the roll-out of a refreshed employee development programme and we are pleased to have welcomed a new Chief Commercial Officer, Dino Labbate, who joined in January 2025.

 

Euan Sutherland, Chief Executive, commented:

"A.G. BARR is in line to deliver another year of strong top line growth, margin improvement and cash generation. These headline metrics highlight excellent progress towards our long-term financial goals. We have sustained brand momentum despite the well trailed wider market pressures, and continue to make good progress towards our margin target.

We are committed to consistent long-term revenue growth and have confidence in further margin improvement as per our previous guidance. Our expectations for 2025/26 are unchanged and in line with market expectations2."

Future Events

Full year results for 2024/25 year will be reported on 25 March 2025. In addition, the business plans to hold analyst and investor visits to its Cumbernauld and Milton Keynes sites in the spring and a Capital Markets event in June.

 

Proposed analyst and investor factory and market visit dates are as follows:

Cumbernauld 23 April 2025

Milton Keynes 15 May 2025

Notes

1 - adjusted profit before tax

2 - Analyst consensus:

● FY 2024/25: revenue £420.1m; adjusted PBT £57.4m; adjusted operating margin 13.4%

● FY 2025/26: revenue £439.4m; adjusted PBT £65.0m; adjusted operating margin 14.5%

Note: This is based on estimates of analysts who have updated forecasts over the past 6 months

 

For more information, please contact :

A.G. BARR Instinctif Partners

0330 390 3900 020 7457 2010/05

Euan Sutherland Chief Executive Justine Warren

Stuart Lorimer, Finance Director Matthew Smallwood

Hannah Scott

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTPPUQGGUPAGRM
Date   Source Headline
8th Sep 20222:08 pmRNSDirector/PDMR Shareholding
31st Aug 202210:29 amRNSNotice of Interim Results Date
8th Aug 20221:05 pmRNSDirector/PDMR Shareholding
2nd Aug 20227:00 amRNSTrading Update
11th Jul 202210:32 amRNSDirector/PDMR Shareholding
16th Jun 202210:14 amRNSDirector/PDMR Shareholding
16th Jun 202210:04 amRNSDirector/PDMR Shareholding
15th Jun 202210:23 amRNSDirector/PDMR Shareholding
13th Jun 20221:42 pmRNSDirector/PDMR Shareholding
13th Jun 20221:40 pmRNSDirector/PDMR Shareholding
8th Jun 20229:53 amRNSDirectorship
27th May 20221:55 pmRNSResult of AGM
23rd May 20229:55 amRNSDirector/PDMR Shareholding
11th May 20228:53 amRNSDirector/PDMR Shareholding
26th Apr 20229:08 amRNSAnnual Financial Report / Notice of AGM
11th Apr 20221:11 pmRNSDirector/PDMR Shareholding
11th Apr 20228:51 amRNSDirector/PDMR Shareholding
11th Apr 20228:45 amRNSDirector/PDMR Shareholding
30th Mar 20227:00 amRNSDirectorate Change
29th Mar 20222:34 pmRNSDirector/PDMR Shareholding
29th Mar 20229:37 amRNSCorrection: Final results year ended 30 Jan 2022
29th Mar 20227:00 amRNSFinal results for the year ended 30 January 2022
18th Mar 20229:02 amRNSHolding(s) in Company
8th Mar 20222:14 pmRNSDirector/PDMR Shareholding
9th Feb 20227:56 amRNSDirector/PDMR Shareholding
4th Feb 20228:32 amRNSHolding(s) in Company
4th Feb 20228:27 amRNSHolding(s) in Company
1st Feb 20227:00 amRNSTrading Update
26th Jan 202210:35 amRNSNotice of Trading Update
11th Jan 202211:28 amRNSDirector/PDMR Shareholding
8th Dec 202112:59 pmRNSDirector/PDMR Shareholding
6th Dec 20217:00 amRNSInvestment in MOMA Foods Limited
29th Nov 20217:00 amRNSTrading Update
8th Nov 20212:15 pmRNSDirector/PDMR Shareholding
3rd Nov 20211:21 pmRNSDirector/PDMR Shareholding
3rd Nov 20219:37 amRNSDirector/PDMR Shareholding
1st Nov 202112:50 pmRNSDirector/PDMR Shareholding
11th Oct 20212:15 pmRNSDirector/PDMR Shareholding
11th Oct 20218:12 amRNSDirector/PDMR Shareholding
1st Oct 20218:49 amRNSDirector/PDMR Shareholding
1st Oct 20218:33 amRNSDirector/PDMR Shareholding
28th Sep 20217:00 amRNSInterim results
8th Sep 202111:39 amRNSDirector/PDMR Shareholding
31st Aug 202110:37 amRNSNotice of Interim Results Date
9th Aug 202111:21 amRNSDirector/PDMR Shareholding
3rd Aug 20217:00 amRNSH1 trading update to 1 August 2021
20th Jul 20217:00 amRNSTrading Update
19th Jul 20212:22 pmRNSHolding(s) in Company
9th Jul 20217:55 amRNSDirector/PDMR Shareholding
6th Jul 20213:32 pmRNSDirector/PDMR Shareholding - AMENDMENT

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.